1. Show article details.

    BRIEF-Meridian Bioscience Reports Third Quarter Adjusted Non-GAAP Earnings Per Share Of $0.16

    Reuters – 7:52 AM ET 07/30/2019

    Meridian Bioscience Inc (VIVO): * MERIDIAN BIOSCIENCE REPORTS THIRD QUARTER 2019 OPERATING RESULTS. * Q3 ADJUSTED NON-GAAP EARNINGS PER SHARE $0.16. * Q3 GAAP EARNINGS PER SHARE $0.12. * Q3 EARNINGS PER SHARE ESTIMATE $0.09 -- REFINITIV IBES DATA. * QTRLY CONSOLIDATED REVENUE DECREASED 6% TO $48.4 MILLION.

  2. Show article details.

    Meridian Bioscience Reports Third Quarter 2019 Operating Results

    GlobeNewswire – 7:30 AM ET 07/30/2019

    Meridian Bioscience, Inc. (VIVO) today announced financial results for the third quarter and first nine months ended June 30, 2019. Third Quarter 2019 Highlights: June Year-to-Date Fiscal 2019 Highlights: Third Quarter Fiscal 2019 ResultsConsolidated revenue for the third quarter of fiscal 2019 decreased 6% to $48.4 million, compared to $51.7 million last year.

  3. Show article details.

    Meridian Bioscience to Hold Third Quarter 2019 Financial Results Conference Call on July 30, 2019

    GlobeNewswire – 4:30 PM ET 07/10/2019

    Meridian Bioscience, Inc. (VIVO), a provider of diagnostic testing solutions and life science raw materials will report third quarter 2019 financial results Tuesday, July 30, 2019.

  4. Show article details.

    InMed Pharmaceuticals Appoints Catherine Sazdanoff to Board of Directors

    PR Newswire – 7:25 AM ET 07/02/2019

    TSX:INOTCQX:IMLFF VANCOUVER, July 2, 2019  InMed Pharmaceuticals Inc. (IMLFF), a biopharmaceutical company developing a proprietary biosynthesis technology for cannabinoid-based pharmaceuticals to treat severe diseases, today announced the appointment of Catherine Sazdanoff, JD, to its Board of Directors. Eric A. Adams, President and Chief Executive Officer.

  5. Show article details.

    BRIEF-Meridian Bioscience Says Co And Eric Rasmussen Entered Into A Separation Agreement

    Reuters – 9:19 AM ET 06/25/2019

    Meridian Bioscience Inc (VIVO): * Meridian Bioscience Inc (VIVO) - ON JUNE 21, 2019, CO AND ERIC S. RASMUSSEN ENTERED INTO A SEPARATION AGREEMENT. * MERIDIAN BIOSCIENCE (VIVO) - RASMUSSEN'S LAST DAY OF EMPLOYMENT AS MERIDIAN'S EXECUTIVE VICE PRESIDENT AND CFO SHALL BE JUNE 28, 2019.

  6. Show article details.

    Meridian Bioscience Announces Closing of Transaction to Acquire Business of GenePOC

    GlobeNewswire – 4:28 PM ET 06/03/2019

    Meridian Bioscience, Inc. (VIVO), a provider of diagnostic testing solutions and life science raw materials, today announced it has completed its previously announced acquisition of the business of GenePOC Inc., a Quebec City, Quebec, Canada based provider of molecular diagnostic instruments and assays.

  7. Show article details.

    Meridian Bioscience Reports Second Quarter 2019 Operating Results, Suspends Quarterly Cash Dividend, and Provides Fiscal 2019 Guidance for Pending Acquisition

    GlobeNewswire – 9:42 AM ET 04/30/2019

    Meridian Bioscience, Inc. (VIVO) today announced financial results for the second quarter and first six months ended March 31, 2019. Second Quarter 2019 Highlights: Year-to-Date Fiscal 2019 Highlights: Second Quarter 2019 Results Total revenue for the second quarter of fiscal 2019 decreased 11% to $50.2 million, compared to $56.5 million in the second quarter of 2018.

  8. Show article details.

    Meridian Bioscience Announces Agreement to Acquire Business of GenePOC; Adds State-of-the-Art Molecular Diagnostics Platform

    GlobeNewswire – 9:41 AM ET 04/30/2019

    Meridian Bioscience, Inc. (VIVO), a provider of diagnostic testing solutions and life science raw materials, today announced it has entered into a definitive agreement to acquire the business of GenePOC Inc., a Quebec City, Quebec, Canada based provider of molecular diagnostic instruments and assays.

  9. Show article details.

    Meridian Launches a New Inhibitor Tolerant qPCR Reagent to Significantly Simplify Molecular Diagnostic Workflows From Crude Samples

    GlobeNewswire – 8:48 AM ET 04/18/2019

    Meridian Bioscience, Inc. (VIVO) today announced the launch of its Inhibitor-tolerant qPCR Mix, a novel mix to accelerate workflows and improve DNA target amplification and quantification from crude samples; adding to its growing portfolio of molecular diagnostic products.

  10. Show article details.

    Meridian Bioscience to Hold Second Quarter 2019 Financial Results Conference Call on April 30, 2019

    GlobeNewswire – 4:55 PM ET 04/10/2019

    Meridian Bioscience, Inc. (VIVO), a provider of diagnostic testing solutions and life science raw materials will report second quarter 2019 financial results Tuesday, April 30, 2019. Jack Kenny, Chief Executive Officer, and Eric Rasmussen, Chief Financial Officer, will host a conference call beginning at 10:00 a.m. Eastern Time to discuss the results and answer questions.

  11. Show article details.

    Meridian Bioscience Announces Preliminary Second Quarter 2019 Revenue Results; Updates Fiscal 2019 Guidance

    GlobeNewswire – 6:59 AM ET 04/02/2019

    Meridian Bioscience, Inc. (VIVO), a provider of diagnostic testing solutions and life science raw materials, today provided a business update including preliminary sales results for its second fiscal quarter and revised financial guidance for fiscal 2019.

Page:

Today's and Upcoming Events

  • Nov
    11

    VIVO to announce Q4 earnings (Unconfirmed)

Past Events (last 90 days)

  • Jul
    30

    VIVO announced Q3 earnings.

Data provided by Thomson Reuters © 2019

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.